Evaluation of lung volume loss with 3D CT volumetry in COVID-19 patients.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

5 citing papers in PubMed.

1. Basilar segmentectomy for early-stage non-small cell lung cancer: is it worth preserving the S6 segment?Journal of thoracic disease · 2026
   Article
2. Lung volume measurement using chest CT in COVID-19 patients: a cohort study in Japan.BMJ open respiratory research · 2024
   Article
3. COVID-19 progression in hospitalized patients using follow-upJournal of thoracic disease · 2023
   Article
4. Evaluation of the models generated from clinical features and deep learning-based segmentations: Can thoracic CT on admission help us to predict hospitalized COVID-19 patients who will require intensive care?BMC medical imaging · 2022
   Article
5. Rapid progression of COVID-19 pneumonia to extensive fibrosis assessed with 3D volumetric CT.Diagnostic and interventional radiology (Ankara, Turkey) · 2021
   Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

2 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as